Rahhal Dina N, Xu Hong, Huang Wei-Chao, Wu Shengli, Wen Yujie, Huang Yiming, Ildstad Suzanne T
Institute for Cellular Therapeutics, University of Louisville, Louisville, KY 40202-1760, USA.
Transplantation. 2009 Sep 27;88(6):773-81. doi: 10.1097/TP.0b013e3181b47cfa.
Mixed chimerism induces donor-specific tolerance to composite tissue allotransplants (CTAs). In the present studies, we used a nonmyeloablative conditioning approach to establish chimerism and promote CTA acceptance.
Wistar Furth (RT1A(u)) rats were conditioned with 600 to 300 cGy total body irradiation (TBI, day-1), and 100 x 10(6) T-cell-depleted ACI (RT1A(abl)) bone marrow cells were transplanted on day 0, followed by a 11-day course of tacrolimus and one dose of antilymphocyte serum (day 10). Heterotopic osteomyocutaneous flap transplantation was performed 4 to 6 weeks after bone marrow transplantation.
Mixed chimerism was initially achieved in almost all recipients, but long-term acceptance of CTA was only achieved in rats treated with 600 cGy TBI. When anti-alphabeta-T-cell receptor (TCR) monoclonal antibody (mAb) (day-3) was added into the regimens, donor chimerism was similar to recipients preconditioned without anti-alphabeta-TCR mAb. However, the long-term CTA survival was significantly improved in chimeras receiving more than or equal to 300 cGy TBI plus anti-alphabeta-TCR mAb. Higher levels of donor chimerism were associated with CTA acceptance. The majority of flap acceptors lost peripheral blood chimerism within 6 months. However, donor chimerism persisted in the transplanted bone at significantly higher levels compared with other hematopoietic compartments. The compartment donor chimerism may be responsible for the maintenance of tolerance to CTA. Long-term acceptors were tolerant to a donor skin graft challenge even in the absence of peripheral blood chimerism.
Mixed chimerism established by nonmyeloablative conditioning induces long-term acceptance of CTA, which is associated with persistent chimerism preferentially in the transplanted donor bone.
混合嵌合体可诱导对复合组织同种异体移植(CTA)的供体特异性耐受。在本研究中,我们采用非清髓性预处理方法来建立嵌合体并促进CTA的接受。
对Wistar Furth(RT1A(u))大鼠进行600至300 cGy的全身照射(TBI,第-1天),并于第0天移植100×10⁶个去除T细胞的ACI(RT1A(abl))骨髓细胞,随后给予11天的他克莫司疗程和一剂抗淋巴细胞血清(第10天)。骨髓移植后4至6周进行异位骨肌皮瓣移植。
几乎所有受体最初都实现了混合嵌合体,但只有接受600 cGy TBI治疗的大鼠实现了CTA的长期接受。当在方案中加入抗αβ-T细胞受体(TCR)单克隆抗体(mAb)(第-3天)时,供体嵌合体与未使用抗αβ-TCR mAb预处理的受体相似。然而,接受大于或等于300 cGy TBI加抗αβ-TCR mAb的嵌合体的长期CTA存活显著改善。更高水平的供体嵌合体与CTA的接受相关。大多数皮瓣接受者在6个月内失去外周血嵌合体。然而,与其他造血区室相比,供体嵌合体在移植骨中持续存在的水平显著更高。区室供体嵌合体可能是维持对CTA耐受的原因。即使在没有外周血嵌合体的情况下,长期接受者也能耐受供体皮肤移植挑战。
通过非清髓性预处理建立的混合嵌合体可诱导CTA的长期接受,这与移植的供体骨中优先持续存在的嵌合体有关。